Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry SummitGlobeNewsWire • 09/14/22
Nasdaq Bear Market: 2 Top Growth Stocks You'll Wish You'd Bought on the DipThe Motley Fool • 09/05/22
Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP InhibitorGlobeNewsWire • 09/01/22
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, AxsomeInvestors Business Daily • 08/30/22
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And OthersInvestors Business Daily • 08/29/22
Axsome Therapeutics Rockets After Winning FDA Approval For A New Depression DrugInvestors Business Daily • 08/19/22
Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in AdultsGlobeNewsWire • 08/19/22